Abstract: The present invention relates to Bacillus licheniformis B1 strain, alkalophilic enzyme solution and a method for preparing the same, in particular the method for producing cellulase demonstrating optimal activity at pH 10-13 by using Bacillus licheniformis B1 strain. The enzyme produced by the method of the present invention and the enzyme solution containing the same have excellent enzyme activity in alkali condition, so that they can be effectively applied in diverse uses including the production of detergent or bio-fuel.

Abstract: A live attenuated derivative of a pathogenic bacterium intended for use as a vaccine.

Abstract: The present invention is directed to diagnostic devices and methods for detecting Trichomonas infections.

Abstract: The invention concerns novel Salmonella enterica attenuated strains, characterized in that they are inactivated at the level of the znuABC operon through mutation in at least one of the znuA, znuB, znuC genes of such operon, for uses in medical or veterinary fields as vaccines.

Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for inhibiting or treating inflammatory lung disease by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.

Abstract: The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5?- or 3?-end. These oligonucleotides have either reduced or improved immunostimulatory properties. The invention establishes that 5?-terminal secondary structures affect immunostimulatory activity significantly more than those at the 3?-end. The invention also provides methods for increasing or decreasing the immunostimulatory activity of a CpG-containing nucleic acid.

Abstract: Safe and effective live vaccines against Aeromonas hydrophila of fish were created through the induction of rifampicin resistance in native Aeromonas hydrophila isolates; these including rifampicin-resistant mutants NRRL-B-50040 and NRRL-B-50041. Single immersion exposure of fish stimulated acquired immunity against virulent Aeromonas hydrophila infection.

Abstract: The present invention relates to two-component lantibiotics isolated from Bacillus sp. Methods for producing said lantibiotics are provided, wherein dehydration and cyclization of the peptides is carried out by two substrate-specific modifying enzymes. Given the antimicrobial activity of the instant lantibiotics, methods for preventing or treating bacterial infections are also provided.

Abstract: An object of the present invention is to provide a novel microalga that produces hydrocarbons available as an alternative fuel to a diesel fuel (light oil). The present invention relates to a novel microalga Pseudochoricystis ellipsoidea having the ability to produce hydrocarbons, and to a process for producing hydrocarbons, characterized by culturing a microalga belonging to the genus Pseudochoricystis or the genus Choricystis having the ability to produce hydrocarbons, and collecting the hydrocarbon from the resulting cultured product.

Abstract: The present disclosure relates to T24 nucleic acid sequences, amino acid sequences, and antibodies. Methods for detecting and diagnosing Taenia solium infection in a subject using the T24 sequences and specific binding agents are also disclosed. The T24 sequences disclosed herein can be formulated into a pharmaceutical composition for administration to a subject. For example, the disclosed T24 polypeptides can also be administered to a subject to stimulate an immune response in the subject, thereby protecting the subject against T. solium infection.

Abstract: The invention provides methods and compositions for the detection of Ehrlichia chaffeensis.

Abstract: The invention relates to attenuate mutated strains of apicomplex of a family of Sarcocystidae, containing inactivated MIC1 and MIC3 adhesins and to the use thereof for a vaccine.

Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.

Abstract: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.

Abstract: A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.

Abstract: The present invention relates to the use of bacteria of the species Streptococcus phocae for the manufacture of a vaccine, to methods for the production of such vaccines, to bacteria of the species Streptococcus phocae for use in a vaccine and to methods for the combating of Streptococcus phocae infection in fish.

Abstract: The present invention provides molecular methods for efficiently transforming the genome of common disease-transmitting parasites, such as Plasmodium falciparum. The transformation efficiencies are improved up to 100 times over those conventionally known. The methods provide high saturation of the target parasite genome, of 50% or greater, and target non-specifically TTAA-rich sites in the parasite genome. The invention also discloses a model that may be used to functionally annotate the genome of the Plasmodium falciparum, thus permitting the design and screening of compounds that may be useful in the control and inhibiting of diseases caused and transmitted by these parasites, including malaria. Highly efficient and multi-site integrating transposons, particularly piggyBac transposons, which provide for random and multi-site integration into parasite genomes in the presence of a helper plasmid, are also presented.

Abstract: The present invention relates to mucosal vaccine adjuvants containing flagellins, the structural component of flagella, originated from Vibrio vulnificus, Salmonella typhimurium, and Listeria monocytogenes as an active component.

Abstract: Targeted disruption of the centrin gene leads to attenuation of growth in Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation of immunological and diagnostic reagents. Other preferred embodiments provide related immunogenic compositions, methods of generating an immune response, methods for producing a vaccine, and methods of forming attenuated strains of Leishmania.

Abstract: It is an object of the present invention to provide a polynucleotide, which can effectively suppress the immunoreactivity caused by DNA having a CpG motif and which can be used for preventing and/or treating immune-mediated diseases such as arthritis. The present invention provides a polynucleotide comprising a CpG motif wherein guanine is methylated, and a pharmaceutical composition comprising the above-mentioned polynucleotide.